Previous 10 | Next 10 |
BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces dosing of the first subjects in a Phase 1 clinical trial with its oral, first-in-class pan-norovirus and pan-coronavirus 3CL protease in...
2023-08-14 13:54:56 ET Cocrystal Pharma press release ( NASDAQ: COCP ): Q2 GAAP EPS of -$0.50. Cocrystal reported unrestricted cash as of June 30, 2023 of $32.4 million, compared with $37.1 million as of December 31, 2022. For further details see: Cocrystal Pharm...
On track to begin a Phase 2a trial in the second half of 2023 with CC-42344 for the treatment of pandemic and seasonal influenza A Selected the novel protease inhibitor CDI-988 as development lead in the oral norovirus progra...
F irst dual coronavirus - norovirus oral antiviral is scheduled for Phase 1 in healthy volunteers In vitro studies show broad-spectrum activity against noroviruses including GII.4 pandemic strains N o approved treatments or vacci...
2023-05-31 08:27:50 ET Cocrystal Pharma ( NASDAQ: COCP ), a biotech focused on antiviral therapies, announced Wednesday that the company received approval to conduct a Phase 1 trial for its oral COVID-19 therapy CDI-988 in Australia. The permission from the Australian Human Rese...
BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces approval from the Australian Human Research Ethics Committee (HREC) to conduct a Phase 1 study with its novel, oral, broad-spectrum 3CL protease inhibitor CDI-988 as a pot...
2023-05-17 19:43:06 ET Summary Pardes Biosciences Seeking Strategic Alternatives. Pardes’ Pipeline is depleted. All-Star management team in place. Significant cash available. Pardes Biosciences Seeking Strategic Alternatives Could See Consolidation Par...
2023-05-15 09:58:13 ET Cocrystal Pharma press release ( NASDAQ: COCP ): Q1 GAAP EPS of -$0.64 misses by $0.05 . Cocrystal reported unrestricted cash as of March 31, 2023 of $34.0 million, compared with $37.1 million as of December 31, 2022. Research and development...
BOTHELL, Wash., May 15, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three months ended March 31, 2023 and provides updates on its antiviral pipeline, upcoming milestones and business activities. “Re...
BOTHELL, Wash., May 04, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that new data from its CC-42344 Phase 1 influenza A Study was presented today by Sam Lee, Ph.D., President and co-CEO, at the 7 th Annual International Society for I...
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently ...
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected ...
BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human...